CFO Corner: Iker Etxezarreta Fraile, Faes Farma

Why It Matters

The CFO’s agenda signals a shift toward financially disciplined, innovation‑focused growth in European pharma, positioning Faes Farma to compete globally while navigating AI‑driven change.

Key Takeaways

• Strengthening governance and transparent finance communication at Faes Farma
• Positioning FP&A as strategic partner for decision‑making
• Prioritizing capital allocation and liquidity to support growth ambitions
• Emphasizing talent development and continuous process improvement
• Advocating EU public‑private collaboration to boost pharma innovation

Pulse Analysis

The interview with Iker Etxezarreta, CFO of Spain‑based Faes Farma, reveals a clear shift toward disciplined financial governance in the European pharma sector. By tightening internal controls and fostering transparent communication across finance functions, the company aims to reduce operational friction and improve risk oversight. Etxezarreta also wants the Financial Planning & Analysis (FP&A) unit to move beyond reporting, acting as a strategic partner that links historical performance with forward‑looking scenarios. Coupled with a focus on capital allocation and liquidity management, these steps are designed to fund long‑term growth while keeping debt at sustainable levels.

Talent and process efficiency emerge as equally critical levers. Etxezarreta spends considerable time mapping internal skill sets, nurturing curiosity, and creating clear career pathways to retain high‑performing staff. Continuous, incremental process upgrades are pursued to align finance with the rapid pace of product development and market entry. The CFO also highlights the role of digital‑native talent in accelerating AI‑driven transformation, noting that Faes Farma is already embedding machine‑learning tools to streamline forecasting and scenario analysis. This pragmatic approach balances hype with tangible value creation.

Beyond the company level, Etxezarreta warns that Europe’s pharmaceutical competitiveness hinges on a robust innovation ecosystem. Recent shocks—from COVID‑19 to geopolitical tensions—have exposed structural gaps, especially when compared with the United States and China. He calls for stronger public‑private partnerships, stable incentives, and coordinated AI adoption to keep European drug development on the cutting edge. By aligning financial strategy with policy support, firms like Faes Farma can better navigate funding cycles, attract research talent, and ultimately deliver new therapies that sustain the continent’s health‑care leadership.